Treatment After Crizotinib Resistance in ALK plus Non-Small-Cell Lung Cancer
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.27, sa.1, ss.60-68, 2017 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 27 Sayı: 1
- Basım Tarihi: 2017
- Doi Numarası: 10.4999/uhod.171786
- Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.60-68
- Anahtar Kelimeler: Non-small-cell lung cancer, ALK, Crizotinib, Resistance
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Systemic chemotherapy, genotype-based targeted therapies and immunotherapy are widely used in the treatment of advanced non small-cell lung cancer (NSCLC). Among the targeted therapies, the agents targeting the epidermal growth factor receptor (EGFR), the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement and C-ros oncogene 1 (ROS-1) have currently become standard treatment for cases presenting such molecular anomalies. Of them, cases with ALK-rearrangement displayed dramatic results with a first generation ALK-inhibitor crizotinib; however, most of the patients develop a resistance in a few years. Especially the central nervous system relapses pose the most common clinical problem. Next generation ALK-inhibitors are promising with a high level of effectiveness in this resistance, in which various molecular mechanisms take part. Also, it gains increasing importance to re-perform a biopsy in the progression stage and reveal the mechanisms causing the secondary resistance in those patients.